ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentSchlierenAthebio AG
Athebio AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Athebio AG is the development and provision of proprietary technology for the creation of targeted therapeutics with improved efficacy and safety, particularly through the use of "plug & play" DARPin technology (Athebody). The company focuses on partnering with pharmaceutical companies to develop and market innovative medicines.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Athebio AG

✓ Offered7
Athebody® platform
Athebody® DARPin platform for targeted biotherapeutics, with modular binding domains, high specificity, solubility and stability, as well as multi-specificity and protein fusion options.
Drug-Discovery-Engine
In-vitro discovery engine for the selection of binders with controlled target quality and high library diversity for preclinical and clinical development.
Partnering for biotherapeutic development projects
Flexible partnership models, joint project teams, and access to Athebody® technology for drug developers and biotherapeutics development.
Targeted AAV development
Development of targeted adeno-associated viruses for viral gene therapy, for example for neurology and ophthalmology, for directed DNA delivery into target tissues.
Targeted LNP development
Development of targeted lipid nanoparticles for non-viral gene therapy, for directed mRNA delivery into the desired tissue, for example in oncology or infectious diseases.
T-cell Receptor Mimetics (TCRms)
Development of T-cell receptor mimetics for immuno-oncology, with targeted control of immune cells against tumor cells bearing specific pHLAx markers.
Targeted Radio Therapy (tRT)
Development of targeted radiotherapies for radio-oncology, with precise targeting of therapeutic radionuclides to tumor cells with specific markers.
Trust & reputation

ranQ Trust Score of Athebio AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

Athebio AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Athebio AG scores 81.6 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.75.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
Athebio AG scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
Athebio AG scores 30.7 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.51.44%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.10.04%
Qualifications+0.00

Athebio AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

February 7, 2022Media
Athebio enters collaboration agreement in the field of gene therapy
startupticker.ch

Knowledge

No knowledge articles yet

Once Athebio AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Athebio AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Athebio AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Athebio AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Wagistrasse 18
8952 Schlieren

At a glance

Legal form
Corporation
UID
CHE-259.171.415
Founded
2019 · 7 years
Last commercial register change
December 22, 2025
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    MA
    Mabylon AG
    Schlieren
    IB
    InterAx Biotech AG
    Schlieren
    NA
    Neurimmune AG
    Schlieren
    PB
    Proxima Bio GmbH
    Schlieren
    CR
    Charles River Laboratories Switzerland AG
    Hettlingen
    IG
    inSili.com GmbH
    Zurich
    PA
    Philochem AG
    Otelfingen
    EA
    EVIIVE AG
    Obfelden